Diagnostic value of next-generation sequencing in an unusual sphenoid tumor.
Farzad Jamshidi, Erin Pleasance, Yvonne Li...
https://pubmed.ncbi.nlm.nih.gov/24807916Actively Recruiting
Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID02155621
Personalized OncoGenomics (POG) Program of British Columbia: Connecting Cancer Genomics to Cancer Care
Led by British Columbia Cancer Agency · Updated on 2025-09-22
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
B
BC Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how the genetic diversity of cancers affects treatment by using full genome sequencing to identify specific genetic changes driving cancer growth. The study focuses on patients with metastatic or incurable cancers, aiming to match each individual's cancer profile with targeted therapies based on their unique molecular signatures. This personalized approach hopes to guide chemotherapy choices and improve understanding of cancer genetics across different patients. Participants will undergo biopsies to collect fresh tumor samples and blood for normal DNA comparison. Comprehensive DNA and RNA sequencing is performed, followed by detailed bioinformatic analysis to detect mutations and gene expression changes that may serve as treatment targets. The study team regularly reviews genomic data to recommend possible systemic therapies and match patients to clinical trials when available. This program has evolved over several phases and is integrated with clinical trials to apply genomic findings to cancer care. Throughout the study, participants will provide tumor biopsies, blood samples, and archival tissue if available. Researchers analyze genetic data and discuss findings weekly to guide treatment decisions. The study measures the impact of genomic data on clinical decision-making and catalogs cancer genomes over five years. Participation includes ongoing monitoring and data sharing with research collaborators, with a total duration aligned with the program's long-term goals.
CONDITIONS
Brief Title
Personalized Oncogenomics (POG) Program of British Columbia
Who Can Participate
Age: 18Years - 85Years
All Genders
Eligibility Criteria
You may qualify if you...
- Patients must agree to allow their archival specimens to be used and possibly completely depleted for analyses.
- Willing and able to have a study-specific biopsy or resection of the tumor or metastatic site, or have adequate archival material collected within 16 weeks of consent.
- Patients must agree to provide a blood test or other sample of normal DNA for germline genomic analysis.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Age 18 years or older.
- Estimated life expectancy of 6 months or more and likely to be fit for a therapeutic clinical trial in 3 to 6 months.
- Measurable disease according to RECIST v1.1 or updated version.
- Adequate organ function.
- Understanding that data may guide treatment recommendations, including use or avoidance of chemotherapy agents.
- Willingness to have de-identified genomic and clinical data shared with research collaborators.
- Willingness to be contacted for future studies based on generated data.
You will not qualify if you...
- Unable or unwilling to consent to tissue and blood sample requirements.
- Significant medical condition making participation unsuitable, including inability to join a clinical trial within 12 weeks after biopsy.
- Unwilling or unable to provide treatment and outcome follow-up information to investigators.
- Unwilling to receive medically actionable findings from germline or somatic analyses.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Genome Sequencing
Duration - Time required for biopsy, sample processing, and genomic analysis as per protocol
Participants undergo tumor biopsy and blood sample collection for genomic sequencing and analysis to identify cancer mutations and potential treatment targets.
1 visit for biopsy and blood sample collection
Follow-up
Duration - Up to 5 years
Participants are monitored for clinical decision-making and treatment guidance based on genomic data and may be contacted for future studies.
Visits as needed for clinical follow-up and outcome assessments
Trial Site Locations
Total: 1 location
1
BC Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
Loading map...
Research Team
J
Janessa J Laskin, MD
M
Marco Marra, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Steven Jm Jones, Janessa Laskin, Yvonne Y Li...
https://pubmed.ncbi.nlm.nih.gov/20696054Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Janessa Laskin, Steven Jones, Samuel Aparicio...
https://pubmed.ncbi.nlm.nih.gov/27148575Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
Irene S Yu, Kathleen Wee, Laura Williamson...
https://pubmed.ncbi.nlm.nih.gov/35726793Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Jean-Michel Lavoie, Teresa Mitchell, Sung-Eun Lee...
https://pubmed.ncbi.nlm.nih.gov/31907737Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer.
Joanna M Karasinska, James T Topham, Steve E Kalloger...
https://pubmed.ncbi.nlm.nih.gov/31481506The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system.
Derek Wong, Yaoqing Shen, Adrian B Levine...
https://pubmed.ncbi.nlm.nih.gov/31371350Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Laura M Williamson, Michael Steel, Jasleen K Grewal...
https://pubmed.ncbi.nlm.nih.gov/31160355Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.
My Linh Thibodeau, Eric Y Zhao, Caralyn Reisle...
https://pubmed.ncbi.nlm.nih.gov/30833417Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
Hui-Li Wong, Kevin C Yang, Yaoqing Shen...
https://pubmed.ncbi.nlm.nih.gov/29092957